Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of Biomarkers Based on DNA Methylation in the NCAPH2/LMF2 Promoter Region for Diagnosis of Alzheimer’s Disease and Amnesic Mild Cognitive Impairment

7 Jan 2016

Abstract excerpt

From the standpoint of early interventions for dementia, a convenient method of diagnosis using biomarkers is required for Alzheimer's disease (AD) in the early stage as well as amnesic mild cognitive impairment (aMCI). Focusing on differences in DNA methylation due to AD and aMCI, in the present study, we first conducted genome-wide screening, measuring blood DNA methylation levels by the Illumina Infinium HD...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dementia and Cognitive Impairment Research
Share to Epigenetics and DNA Methylation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26742120
DOI: 10.1371/journal.pone.0146449

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of Biomarkers Based on DNA Methylation in the NCAPH2/LMF2 Promoter Region for Diagnosis of Alzheimer’s Disease and Amnesic Mild Cognitive ImpairmentPMID 26742120Read ↗

DNA methylation in the NCAPH2/LMF2 promoter region is associated with hippocampal atrophy in Alzheimer's disease and amnesic mild cognitive impairment patients.Semantic proximity Read ↗

Whole genome methylation sequencing in blood from persons with mild cognitive impairment and dementia due to Alzheimer’s disease identifies cognitive statusSemantic proximity Read ↗

Whole genome methylation sequencing in blood from persons with mild cognitive impairment and dementia due to Alzheimer's disease identifies cognitive statusSemantic proximity Read ↗

Altered DNA methylome profiles of blood leukocytes in Chinese patients with mild cognitive impairment and Alzheimer’s diseaseSemantic proximity Read ↗

Whole genome methylation sequencing in blood identifies extensive differential DNA methylation in late‐onset dementia due to Alzheimer's diseaseSemantic proximity Read ↗

Integrated DNA methylation and gene expression profiling across multiple brain regions implicate novel genes in Alzheimer’s diseaseSemantic proximity Read ↗

Methylation-wide association analysis reveals AIM2, DGUOK, GNAI3, and ST14 genes as potential contributors to the Alzheimer’s disease pathogenesisSemantic proximity Read ↗

Towards a Personalized Medicine through Liquid Biopsy in Alzheimer’s disease: Epigenome of cell-free DNA reveals methylation differences linked to APOE statusSemantic proximity Read ↗

Blood‐based multivariate methylation risk score for cognitive impairment and dementiaSemantic proximity Read ↗

Epigenetic genes are differentially methylated in the blood of persons with mild cognitive impairment and Alzheimer’s diseaseSemantic proximity Read ↗

Exploring novel blood-based DNA methylation biomarkers for alzheimer's disease via targeted sequencing of highly variable CpG sites.Semantic proximity Read ↗

Distinct cerebrospinal fluid DNA methylation signatures linked to Alzheimer’s diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.